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ABSTRACT 
Objective: The present research aims to synthesize some new polycyclic compounds including chromene moiety and study their antimicrobial activity. 
Methods: Several new polycyclic systems including chromene scaffold incorporated with pyridine, pyrimidine, imidazopyrimidine, and 
imidazodiazocine were achieved via condensation reaction of chromene derivative under the proper condition with various reagents namely; 
cyanothioacetamide, phenyl isothiocyanate, malononitrile, carbon disulfide, benzaldehyde, triethylorthoformate, and 1,4-dichlorobutane. Moreover, 
a chlorodiazenyl chromene derivative was reacted with some substances possessing active–CH2-bridge such as ethyl cyanoacetate and 
malononitrile to end up with hydrazono compounds. Such compounds were eventually cyclized with hydrazine hydrate to form pyrazole and 
oxopyrazole derivatives. Moreover, compound 1 was treated with benzoyl acetone, and then followed by cyclization with malononitrile to provide 
the corresponding 2-amino14-(4-methoxyphenyl)-4-methy-5-phenyl-14H-benzo[5,6] chromeno [2,3H][1,6]naphthyridine-3-carbonitrile (20). 
Results: The results of the antimicrobial screening in vitro revealed that the inhibition zone (mm) of the synthesized compounds 1-3, 5 and 8 
implied their optimum antibacterial activity, while the compounds 4, 6 and 9-13, 15 showed a moderate to weak antibacterial activity against 
multiple species of B. subtilis, S. aureus, E. coli and P. aeruginosa. In contrast, the compounds 1, 6, 11, 15 showed high antifungal activities against 
different species of A. flavinand C. albicans, while the other compounds exhibit a moderate to poor antifungal activity. 
Conclusion: It is remarkable that a series of chromene derivatives synthesized by a simple and available method leads to a molecule of promising 
antimicrobial activity. Further research is recommended to approve the importance of polycyclic systems for various applications. 
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The resistance of bacteria to antimicrobial drugs is a well-known 
phenomenon [1-2]. As a result, new drugs based on less toxic 
materials are needed and should be designed and developed. The 
chromene nuclei have drawn wide attention for many applications 
in the field of biology, chemotherapy, pharmacology, therapeutical 
chemistry, and materials science. Chromenes are consisting of 
benzene and pyrane fused ring called benzopyrans which used as 
starting materials for the synthesis of bioactive structures [3-25]. 
Since ten years ago, the chromene derivatives have been extensively 
used as active compounds to treat cancer [26, 27] inflammation [28], 
cardiovascular diseases (CVD) [29]. Moreover, they have been used 
as antimicrobial [30-32], antioxidant [33] antiviral [34], 
anthelminthic [35], anti-HIV [36], TNF-α-inhibitor [37], estrogenic 
[38, 39] antitubercular [40-41] herbicidal [42], anticonvulsant, 
antiparkinsonian [43, 44], antidepressant [45] and analgesic [46, 47] 
activity. Moreover, some of chromene scaffold are well known as 
antimicrobial drugs and their analogues such as novobiocin, 
chlorobiocin and coumermycin Al [48-50]. In the present research, 
we aimed to synthesize some new polycyclic compounds including 
chromene moiety and study their antimicrobial activity. 
MATERIALS AND METHODS 
Melting points were determined on the digital melting point 
apparatus (Electrothermal 9100, Electrothermal Engineering Ltd, 
serial No. 8694, Rochford, United Kingdom) and were uncorrected. 
IR data were measured on a Perkin-Elmer 1600 FTIR (Perkin-Elmer, 
USA) in KBr discs. 1H and 13C–NMR spectra were recorded with a 
Bruker Avance spectrometer (300 and 75MHz) (Bruker, Germany) 
in DMSO-d6 and chemical shifts were determined in δppm to TMS as 
the standard internal solvent. Mass spectra (EI) were measured on 
GCMS-QP 1000Ex70ev, Schimadz spectrometer, Japan (EI) at Micro 
Analytical Center, Cairo University, Egypt. Elemental analysis was 
measured by using a Perkin-Elmer microanalysis at 24°C. The new 
derivatives were tested in vitro with respect to their antimicrobial 
activity at the Micro Analytical Center Faculty of Science, Cairo 
University. All reagents and solvents were of commercial grade. 
Synthesis of 11-amino-12-(4-methoxyphenyl)-9-thioxo-9,12-
dihydro-8H-benzo [5,6]chromeno[2,3-b]pyridin-10-carbonitrile (2) 
Cyanothioacetamide (0.01 mol) was added to a mixture of 
compound 1 (0.01 mol) in ethanol (30 ml) including a few drops of 
piperidine. The reaction mixture was allowed to reflux for 8 h then 
cooled down, after that transferred onto ice-cold water, and 
neutralized with HCl (10 %). the filtration process was used to 
separate the resultant solid, which was cleaned and recrystallized 
from ethanol. 
Synthesis of 11-imino-12-(4-methoxyphenyl)–10–phenyl, 10, 
11, dihydro-8H-benzo [5,6] chromeno[2,3-b]pyrimidin-9-(12H) 
thione (3) 
Phenyl isothiocyanate (0.01 mol) was added to the solution of 
compound 1 (0.01 mol) in dry dioxane (20 ml) including 1 ml 
pyridine for 10 h. the reaction mixture was heated under reflux. The 
separated solid was formed after cooling at 25 °C and neutralized 
with HCl (10 %). The precipitated product was filtered, washed with 
H2O, dried and recrystallized from ethanol. 
Synthesis of 9,11-diamino-12–(4-methoxyphenyl)-12H–benzo 
[5,6]chromeno[2,3-b]pyridin-10-carbonitrile (4) 
A solution of compound 1 (0.01 mol) and malononitrile (0.01 mol) in 
absolute ethanol (30 ml) containing a few drops of triethylamine 
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was heated under reflux for 9 h. The obtained solid was filtered and 
recrystallized from ethanol. 
Synthesis of 12-(4-methoxyphenyl)-8,12-dihydro-9H-benzo 
[5,6]chromeno[2,3-d]pyrimidin-9,11(10H)-dithione (5) 
A mixture of compound 1 (0.01 mol) and an aqueous solution of 20 
% KOH in dimethyl sulfoxide (20 ml) was stirred, and then carbon 
disulfide (0.03 mol) was added in several portions during 30 min, 
after 1 h at 25 °C. The precipitated solid was separated, washed 
many times with H2O, and recrystallized from dimethylformamide. 
Synthesis of 2-(4,5-dihydro-1H-imidazol-2-yl)-1-(4-methoxy-
phenyl)-1H-benzo[f]-chromen-3-amine (6) 
To a suspension of compound 1 (0.01 mol) in ethylenediamine (3 
ml), carbon disulfide CS2 (1 ml) was added dropwise and the 
reaction mixture was refluxed underwater bath control for 8 h. After 
cooling, the deposited solid was filtered off, dried, and recrystallized 




A solution of compound 6 (0.01 mol) and benzaldehyde (0.01 mol) 
in absolute ethanol (50 ml) containing 0.1 ml of conc. HCl was 
refluxed for 14 h. After cooling, the separated solid was collected and 
recrystallized from ethanol. 
Synthesis of 14-(4-methoxyphenyl)–2,3,6,14-tetrahydro-5-H-
benzo[5,6]chromeno [3,2-e]imidazo [1,2-c]pyrimidin-5-thione 
(8) 
A mixture of compound 6 (0.01 mol) and carbon disulfide CS2 (10 
ml) in dry pyridine (25 ml) was refluxed under water-bath for 22 h. 
After cooling, the reaction mixture was poured onto cold water. The 
formed solid was filtered off, dried and recrystallized from ethanol. 
Synthesis of 14-(4-methoyphenyl)-3,14-dihydro-2H-benzo [5,6] 
chromeno[3,2-e] imidazo[1,2-c]pyrimidine (9) 
A solution of compound 6 (0.01 mol), triethyl orthoformate (30 ml) 
and acetic anhydride (15 ml) were refluxed for 8h. The precipitate 
that obtained after cooling was filtered, dried and recrystallized 
from benzene. 
Synthesis of 14-(4-methoxyphenyl)-2,3,6,14-tetrahydro-benzo 
[5,6]chromeno[3,2-e]imidazo[1,2-c]pyrimidin-5-one (10) 
A solution of 6 (0.011 mol) with ethylchroformate (0.011 mol) in dry 
pyridine (30 ml) was refluxed for 1 h. The separated solid 




A solution of 6 (0.011 mol) and phenyl isothiocyanate (0.011 ml) in 
dry pyridine (10 ml) was heated under reflux for 7-8 h. After cooling, 
the precipitate was formed by pouring the mixture into cold water 
which filtered off, dried and recrystallized from DMF/ethanol.  
Synthesis of 5-(chloromethyl)-14–(4–methoxyphenyl)–3,14-
dihydro-2H-benzo [5,6]-chromeno[3,2-e]imidazo[1,2-c] pyrimidine 
(12) 
A solution of compound 6 (0.011 mol) and chloroacetyl chloride 
(0.011 mol) in glacial acetic acid (30 ml) was heated under reflux 
overwater bath for 15 min. The precipitate that obtained by adding of 
aqueous sodium acetate was filtered off, dried and recrystallized from 
methanol. 
Synthesis of 17-(4-methoxyphenyl)-2,3,5,6,7,8,16-octahydro-
benzo[5,6]chromeno [3,2-e]imidazo[1,2-a][1,5]diazocine (13) 
A solution of compound 6 (0.01 mol) potassium carbonate anhydrous 
(3.03 g), and1, 4-dichlorobutane (0.01 mol) in dimethylformamide (20 
ml). The reaction mixture was stirred at 60 °C for 9 h. The reaction 
mixture was cooled down by adding cold water (50 ml), and then 
titrated with 10 % hydrochloric acid to reach pH7. The separated 
solid was collected by filtration, washed with distilled water and 
recrystallized from ethanol. 
Diazotization of compound 1:Synthesis of 3–(chlorodiazenyl)–
1–(4-methoxyphenyl)–1H-benzo[f]chromen-2-carbonitrile (14) 
To a suspended solution of compound 1 (0.01 mol) in conc. HCl (3 
ml), a solution of sodium nitrite (0.01 mol) in cold water (2 ml) was 
added over 15 min at 0-5 °C. The diazonium salt was used freshly in 
the next step.  
General procedure for the synthesis of compounds 15, 17 
The diazonium salt solution 14 (0.005 mol) was added slowly to a 
stirred solution of malononitrile and/or ethyl cyanoacetate (0.005 
mol) in acetone (20 ml) at 0-5 °C. The reaction was left overnight 
under stirring at room temperature. The separated product was 
then collected by filtration and washed with ethanol. 
(E)–3-(3,5-diamino-1H-pyrazol–4–y)diazenyl)-1-(4-methoxy-
phenyl)–1H-benzo[f]chromeno-2-carbonitrile (16) 
A solution of compound 15 (0.01 mol) and NH2NH2 99 % (5 ml) in 
ethanol (20 ml) was refluxed for 5 h. The excess solvent was 
evaporated under reduced pressure in vacuum. The separated solid 
was collected by filtration, air-dried and recrystallized from ethanol. 
3–(2,(3-Amino-5-oxo-1,5-dihydro-4H–pyrazol–4–ylidene)-
hydrazinyl)–1H-benzo[f]chromene–2–carbonitrile (18) 
A mixture of compound 17 (0.01 mol) and NH2NH2 99 % (3 ml) in 
absolute ethanol (20 ml) was refluxed for 5 h. The precipitate that 
formed after cooling was filtered off, dried and recrystallized from 
absolute ethanol. 
Synthesis of 1-(11-amino-12-(4-methoxyphenyl)-9-pyhenyl-12H-
benzo [5,6]-chromeno[2,3-b]pyridin-10-yl)ethan-1-one (19) 
The reaction mixture of an equimolar amount of compound 1 (0.012 
mol) and benzoyl acetone (0.012 mol) in ethanol (20 ml) in the 
presence of sodium ethoxide was heated under reflux for 10 h. The 
mixture was cooled down and then poured onto cold H2O. The 
formed solid was collected by filtration and recrystallized from 
ethanol. 
Synthesis of 2-amino14-(4-methoxyphenyl)-4-methy-5-phenyl-
14H-benzo [5,6] chromeno [2,3H][1,6]naphthyridine-3-
carbonitrile (20). 
A mixture of compound 19 (0.012 mol) and malononitrile (0.012 
mol) was allowed to heat under reflux in ethanol (25 ml) including a 
few drops of piperidine as a catalyst for 16 h. The separated solid 
that obtained after cooling was filtered off, washed with cold ethanol 
and recrystallized from DMF/ethanol.  
Antimicrobial evaluation 
Antibacterial and antifungal activity of the newly synthesized 
compounds was determined in vitro by the disc diffusion method 
[51] using a nutrient agar medium against the following 
microorganisms, Staphylococcus aureus (RCMB 29213), Bacillus 
subtilis (RCMB 010010) (Gram-positive bacteria), Escherichia coli 
(RCMB 27853), Pseudomonas aeuroginosa (RCMB 25922) (Gram-
negative bacteria) and fungal species like Candida albicans (RCMB 
05036), Asperigullusflavin (RCMB 02568). All strains were provided 
from the culture collection of the Regional Center for Mycology and 
Biotechnology (RCMB), Al-Azhar University, Cairo, Egypt. Ampicillin 
was the standard drug for antibacterial screening and amphotericin 
B was used as a standard for antifungal screening.  
Method of testing 
The sterilized media was poured onto the sterilized Petri dishes (20 
ml, each Petri dish) and allowed to solidify. Wells of 6 mm diameter 
were made in the solidified media (Nutrient and MacConky agar media 
for bacteria and on Sabouraud dextrose agar for fungus.) with the help 
of sterile borer. A sterile swab was used to evenly distribute microbial 
suspension over the surface of solidified media and solutions of the 
tested samples (5 mg/ml) were added to each well with the help of 
micropipette. The inhibition zones (IZ) of the test compounds were 
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measured after 24-48 h incubation at 37 °C for bacteria and after 5 d 
incubation at 28 °C for fungi. The experiment was performed in 
triplicate and the average zone of inhibition was calculated. 
RESULTS AND DISCUSSION 
Chemistry 
The pathway for the preparation of the target compounds is outlined 
under schemes 1-4. 2-Amino-1-(4-methoxyphenyl)-1H-
benzo[f]chromene-3-carbonitrile (1) is the key compound in our 
study for the production of its functionalized derivatives [52]. 
Compound 1 was condensed with cyanothioacetamideunder basic 
condition to give11-amino-12-(4-methoxyphenyl)-9-thioxo-9,12-
dihydro-8H-benzo[5, 6] chromeno[2,3-b]pyridin-10-carbonitrile (2) 
(Scheme 1). The NMR spectra revealed two D2O replaceable main 
peaks at 6.9 and 8.3 ppm related to the presence of NH2 and NH 
protons. Additionally, compound 1 was allowed to react with phenyl 
isothiocyanatein order to form 11-imino-12-(4-methoxyphenyl)-10-
phenyl,10,11-dihydro-8H-benzo[5, 6]chromeno[2,3-d] pyrimidin-9-
(12H) thione (3). The NMR spectra of compound 3 showed two D2O 
changeable singles at 8.3 and 8.4 ppm corresponding to NH and 
=NH, respectively. Basic catalyzed reaction of 1 with malononitrile 
afforded 9,11-diamino-12-(4-methoxyphenyl)-14,12H-benzo [5,6] 
chromeno[2,3-b]pyridin-10-carbonitrile (4). Interaction of 
compound 1 with carbon disulfide in dimethyl sulfoxide gave 9-
mercapto [2,3-d]pyrimidin-11-thione derivative (5) (Scheme 1). The 
IR spectrum of compound 5 implied characteristic peak at 3100 cm–
1which correlated to the NH group. 
Furthermore, the reaction of 1 with ethylenediamine and a few 
drops of carbon disulfide ended up with 2-imidazolyl benzo 
[f]chromene derivative (6) (Scheme 2). The 1H NMR spectrum of 
compound 6 indicated two D2O replaceable peaks at δ 8.2 and 8.3 
ppm corresponding to NH2 and NH protons, respectively. 
 
 
Scheme 1: Synthesis of benzo [5,6] chromeno [2,3-b]pyridine derivatives 
 
Heating of compound 6 with benzaldehyde resulted in the 
corresponding 5-phenyl-benzochromenoimidazopyrimidine (7) as 
shown in Scheme 2. Moreover, benzochromeno-imidazopyridine-5-
thione (8) was achieved by reaction of compound 6 with carbon 
disulfide as described in Scheme 2. The 1H NMR spectrum of 
compound 8 showed signals at δ 6.8 ppm and δ 8.3 ppm attributed 
to pyridine-C5 proton and NH proton. Polycyclic systems were 
achieved through the reaction of compound 6 with triethyl 




Scheme 2: Synthesis of benzo[5,6]-chromeno[3,2-e]imidazo[1,2-c]pyrimidine derivatives 
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On the other hand, compound 6 was treated with ethyl 
chloroformate in pyridine to produce the imidazo[1,2-c]pyrimidin-5-
one derivative (10). Imidazo [1,2-c]pyrimidin-5-amine derivative 
(11) was obtained via intermolecular cyclization of the compound 6 
with phenyl isothiocyanate. Compound 6 was heated with 
chloroacetyl chloride in glacial acetic acid at 60 °C to provide 5-
(chloromethyl)-14-(4-methoxyphenyl)-3,14-dihydro-2H-benzo [5,6] 
chromeno[3,2-e]imidazo[1,2-c]pyrimidine (12) (Scheme 3). IR data 
of compound 12 indicated a peak at υ 744.5 cm–1 for C-Cl and 
disappearance of NH2 and NH groups that could be related to their 
involvement in the cyclization process. The mass spectrum of 
compound 12 showed a molecular ion peak at m/z 472 (M+, 2%), 
406 (M++2, 8%), which indicate the presence of Cl atom. The cyclo 
condensation of compound 6 with 1,4-dichlorobutane in DMF in the 
presence of anhydrous potassium carbonate led to the formation of 
imidazo[1,2-a][1,5]diazocine derivative (13). 
Benzochromene 2-diazonium chloride 14 was achieved by 
diazotization of compound 1 through its treatment with cold HCl and 
NaNO2 aqueous solution. Coupling of compound 14 with active 
methylene compounds namely; malononitrile and ethylcyanoacetate 
led to the production of the hydrazono derivatives 15 and 17, 
respectively. Pyrazole derivatives 16 and 18 were created through 
the reaction of compounds 15 and/or 17 with hydrazine hydrate.  
Treatment of compound 1 with benzoyl acetone in the presence of 
C2H5ONa led to the formation of 19, which on turn reacted with 
malononitrile under the basic condition to produce benzo [5,6] chromeno 
[3,2,-h] [1,6]naphtharidin-3-carbnitrile derivative (20) (Scheme 4). 
 
 




Scheme 4: Synthesis of benzo[5,6]chromene (16, 18), benzo[5,6]chromeno[2,3-b] pyridine (19) and 
benzo[5,6]chromeno[2,3H][1,6]naphthyridine (20) 
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Spectral characterization of synthesized compounds 
11-Amino-12-(4-methoxyphenyl)-9-thioxo-9,12-dihydro-8H-
benzo[5,6]chromeno[2,3-b]pyridin-10-carbonitrile (2) 
Black crystals; yield 83 %; mp 182 °C; Anal Calcd (%) for C24H17N3O2S 
(411.48): C, 70.05; H, 4.16; N, 10.21; found (%) C, 70.1; H, 4.2; N; 10.1; 
IR (KBr, cm–1): 3379, 3321 (NH, NH2); 3001 for all (CH–aromatic); 
2194 (C≡N); 1562 (C=C), 1273 (C=S); 1H NMR (DMSO–d6, δ ppm): 3.8 
(s, 3H, OCH3), 6.3 (s, 1H, pyran–H), 6.9 (s, 2H, NH2), 7.1-7.9 (m, 10H, 
Ar–H), 8.3 (s, 1H, NH); [13]C–NMR δ: 26.3, 53.9, 63.1, 105.9, 117.9, 
118.1, 118.8, 121.01, 123.6, 127.1, 128.2, 128.5, 128.7, 129.7, 129.8, 
129.9, 131.1, 136.6, 143.8, 150.1, 156.8, 161.8. 
11-Imino-12-(4-methoxyphenyl)–10–phenyl,10,11,dihydro-8H-
benzo[5,6]chromeno[2,3-b]pyrimidin-9-(12H)thione (3) 
Buff crystals; yield 62 %; mp 132 °C; Anal Calcd (%) for C28H21N3O2S 
(463.14): C, 72.55; H, 4.57; N, 9.06; found (%) C, 72.1; H, 4.6; N, 9.1.; 
IR (KBr, cm–1): 3336, 3309 (NH), 3001 (CH–aromatic), 1689 (C=N), 
1527 (C=C), 1277 (C=S); 1H NMR (DMSO-d6, δ ppm): 3.8 (s, 3H, 
OCH3), 6.3 (s, H, pyran–H), 7.0-7.9 (m, 15H, Ar–H), 8.3 (s, 1H, NH, 
D2O exchangeable), 8.5 (s, 1H, NH, D2O exchangeable). 
9,11-Diamino-12–(4-methoxyphenyl)-12H–benzo[5,6] 
chromeno[2,3-b]pyridin-10-carbonitrile (4) 
White powder; yield 83 %; mp 142 °C; Anal Calcd (%) for C24H18N4O2 
(394.14): C, 73.68; H, 4.60; N, 14.20; found (%) C, 73.1; H, 4.5; N, 
14.1; IR (KBr, cm–1): 3390; 3288 (NH2), 3011 (CH–aromatic), 2200 
(CN), 1610 (C=N), 1530 (C=C); 1H NMR (DMSO–d6, δ ppm): 3.8 (s, 
3H, OCH3), 6.3 (s, 1H, pyran–H), 6.8 (s, 2H, NH2, D2O exchangeable), 
6.9 (s, 2H, NH2. D2O exchangeable), 7.1-7.9 (m, 10H, Ar–H). 
12-(4-Methoxyphenyl)-8,12-dihydro-9H-benzo[5,6]chromeno 
[2,3-d]pyrimidin-9,11(10H)-dithione (5) 
White powder; yield 55 %; mp>300 °C; Anal Calcd (%) for 
C22H16N2O2S2 (404.07): C, 65.32; H, 3.99; N, 6.93; found (%) C, 65.1; 
H, 3.5; N, 6.7; IR (KBr, cm–1): 3100 (NH), 3012 (CH–aromatic), 1609 
(C=N), 1531 (C=C); 1H NMR (DMSO-d6, δ ppm): 3.8 (s, 3H, OCH3), 6.3 
(s, 1H, pyran–H), 7.01-7.8 (m, 10H, Ar–H), 8.1(s,1H, NH, D2O, 
exchangeable), 8.3 (s, 1H, NH, D2O exchangeable).  
2-(4,5-Dihydro-1H-imidazol-2-yl)-1-(4-methoxyphenyl)-1H-
benzo[f]-chromen-3-amine (6) 
Black brown powder; yield 65 %; mp 152 °C; Anal Calcd (%) for 
C23H21N3O2 (371.16): C, 74.37; H, 5.70; N, 11.31; found (%): C, 74.1; 
H, 5.6; N, 11.1; IR (KBr, cm–1): 3360, 33.48 (NH, NH2), 3002 (CH-
aromatic), 1604 (C=N), 1573 (C=C); (1H NMR-d6, δ ppm): 3.8 (s, 3H, 
OCH3) 6.3 (s, 1H, pyran-H) 6.55-6.57 (m, 2H, imidazolidine-C4–H), 
6.80-7.00 (m, 2H, imidazolidine–C5–H), 7.1-7.9 (m, 10H, Ar–H), 8.2 
(s, 2H, NH2, D2O exchangeable); 8.3 (s, 1H, NH, D2O 
exchangeable);[13]C, NMR (DMSO-d6, δ ppm):, 21.9, 55.6, 99.5, 
113.2, 118.9, 119.2, 120.6, 121.9, 122.1, 122.5, 123.2, 123.7, 125.4, 
126.3, 127.9, 128.3, 143.5, 158.6, 159.1, 160.1, 160.2. 
14-(4-Methoxyphenyl)-5-phenyl-3,5,6,14-tetrahydro-2H-
benzo[5,6]chromeno[3,2-e]imidazo[1,2-c]pyrimidine (7) 
White crystal; yield 82 %; mp>300 °C; Anal Calcd (%) for C30H25N3O2 
(459.54): C, 78.41; H, 5.48; N, 9.14; found (%): C, 78.1; H, 5.3; N, 9.2. IR 
(KBr, cm–1): 3320 (NH); 3005, (CH-aromatic); 1561 (C=N); 1510 
(C=C);1H NMR (DMSO-d6, δ ppm); 3.1 (s, 3H, OCH3), 3.6 (m, 2H, 
imidazo-C2-H), 3.8 (m, 2H, imidazo–C3-H), 6.3 (s, 1H, pyran–H),, 6.8 (s, 
H, pyrimidine-H), 7.04–7.5 (m, 15H, Ar–H), 8.5 (s, H, NH, D2O 
exchangeable). 
14-(4-Methoxyphenyl)–2,3,6,14-tetrahydro-5-H-benzo 
[5,6]chromeno[3,2-e]imidazo [1,2-c]pyrimidin-5-thione (8) 
Brown powder; yield 70 %; mp 222 °C; Anal Calcd (%) for C24H19N3O2S 
(413): C, 68.7; M, 4.6; N, 10.1; found (%): C, 69.6; H, 4.5; N, 10.2.; IR 
(KBr, cm–1): 3241 (NH); 3000 (CH–aromatic); 1650 (C=N); (C=C), 1447 
(C=S);1H NMR (DMSO-d6, δ ppm): 3.1 (s, 3H, OCH3), 3.6 (m, 2H, 
imidazo–C2-H), 3.8 (m, 2H, imidazo-C3-H), 6.3 (s, 1H, pyran–H), 7.05-
7.9 (m, 10H, Ar–H), 8.4 (s, 1H, NH, D2O exchangeable). 
14-(4-Methoyphenyl)-3,14-dihydro-2H-benzo[5,6]chromeno 
[3,2-e] imidazo[1,2-c] pyrimidine (9) 
Brown powder; yield 75 %: mp 252 °C; Anal Calcd (%) for 
C24H19N3O2 (381.15): C, 75.57; H, 5.02; N, 11.02; found (%): C, 75.1; 
H, 5.1; N, 11.1; IR (KBr, cm–1): 3008 (CH-aromatic); 1601 (C=N), 
1573 (C=C); (1H NMR–d6, δ ppm): 3.1 (s, 3H, OCH3), 3.6 (m, 2H, 
imidazo-C2H), 3.8 (m, 2H, imidazo-C3–H), 6.1 (s, 1H, pyran-H), 6.9 (s, 
H, pyrimidine–H), 7.11-7.58 (m, 10H, Ar–H);[13]C NMR: δ 35.1, 46.1, 
55.1, 57.2, 109.7, 117.2, 117.3, 119.8, 120.8, 120.9, 121.6, 121.8, 




White crystals; yield 65 %; mp>300 °C; Anal Calcd (%): for 
C24H19N3O3 (397.14): C, 72.53; H, 4.82; N, 10.57; found (%): C, 72.4; 
H, 4.7; N, 10.4; IR (KBr, cm–1): 3007 (CH-aromatic), 1602 (C=O), 
1553 (C=C); 1H NMR (DMSO-d6, δ ppm): 3.8 (s, 3H, OCH3), 6.1 (s, H, 
pyran–H), 5.4 (m, 2H, imidazo–C2-H), 6.1 (m, 2H, imidazo-C3-H), 
7.01-7.6 (m, 10H, Ar–H) 8.3 (s, H, NH, D2O exchangeable). 
14-(4-Methoxyphenyl)-N-phyenyl-2,3-dihydro-14H-benzo 
[5,6]chromeno[3,2-e]imidazo[1,2-c] pyrimidin-5-amine (11) 
Brown crystals; yield 65 %; mp 287 °C; Anal Calcd (%) for 
C30H24N4O2 (472.19): C, 76.25; H, 5.12; N, 11.80; found (%). C, 76.1; 
H, 5.1; N, 11.7; IR (KBr, cm–1): 3320 (NH), 3007 (CH–aromatic), 1602 
(C=N), 1510 (C=C);1H NMR (DMSO-d6, δ ppm): 3.8 (s, 3H, OCH3), 6.1 
(s, 1H, pyran–H), 5.3 (m, 2H, imidazo-C2–H), 6.5 (m, 2H, imidazo C3–
H), 7.1–7.9 (m, 15H, Ar–H), 8.3 (s, H, NH, D2O exchangeable);[13]C 
(DMSO-d6, δ ppm): 36.2, 56.0, 57.6, 109.8, 117.1, 117.2, 119.7, 120.9, 
121.0, 123.6, 123.6, 125.3, 127.5, 128.8, 129.4,129.5, 129.6, 129.8, 
129.9, 130.1, 132.2, 142.7, 142.8, 147.1, 160.1, 162.1 
5-(Chloromethyl)-14–(4–methoxyphenyl)–3,14-dihydro-2H-
benzo[5,6]chromeno[3,2-e]imidazo[1,2-c]pyrimidine (12) 
Brown crystal; yield 60 %; mp>300 °C; Anal Calcd (%) for 
C25H20ClN3O2 (429.90) C; 69.85; H, 4.69; N, 9.77; found (%): C; 69.7; 
H, 4.5; N, 9.6; IR (KBr, cm–1): 3001 (CH–aromatic), 1601 (C=N), 1510 
(C=C), 745 (C–Cl);1H NMR (DMSO–d6, δ ppm): 3.1 (s, 3H, OCH3, 3.6 
(m, 2H, imidazo-C2–H), 3.8 (m, 2H, imidazole–C3–H), 6.3 (s, 1H, 
pyran–H), 5.1 (s, 2H, CH2–Cl), 7.1-7.9 (m, 10H, Ar–H) 
17-(4-methoxyphenyl)-2,3,5,6,7,8,16-octahydro-benzo 
[5,6]chromeno[3,2-e]imidazo[1,2-a][1,5]diazocine (13) 
Brown crystals; yield 83 %; mp 177 °C; Anal Calcd (%) for 
C27H27N3O2 (425.21): C, 76.19; H, 6.3; N, 9.8; found (%): C, 76.1; 
H, 9.2; N, 9.1; IR (KBr, cm–1) 3332 (NH); 3005 (CH–aromatic); 
1651 (C=N), 1521(C=C); 1H NMR (DMSO–d6, δppm): 3.1 (m 2H, C-
6–H), 3.3 (m, 2H, C7–H), 3.8 (s, 3H, OCH3), 4.6 (m, 2H, C5–H), 5.1 
(s, H, pyran–H), 5.3 (m, 2H, imidazo–C2–H), 6.5 (m, 2H, imidazo-




Brown crystals; yield 75 %; mp 132 °C; Anal Calcd (%) for 
C24H15N5O2 (405.12): C, 71.10; H, 3.73; N, 17.27; found (%): C, 71.2; 
H, 3.5; N, 17.1; IR (KBr, cm–1) 3332 (NH), 3001 (CH–aromatic), 2198 
(C≡N); 1643 (C=N) 1504 (C=C);1H NMR (DMSO-d6δppm): 3.8 (s, 3H, 




Brown powder; yield 57 %; mp 212 °C; Anal Calcd (%) for 
C24H19N7O2 (437.16): C, 65.89; H, 4.38; N, 22.41; found (%): C, 65.7; 
H, 4.1; N, 22.3; IR (KBr, cm–1): 3387, 3336, 3208 (NH, NH2) 2187 
(CN), 1651 (C=N), 1562 (C=C), 1408 (N=N);1H NMR (DMSO-d6, δ 
ppm): 3.8 (s, 3H, OCH3), 6.1 (s, 1H, pyran–H), 6.9 (s, 1H, NH, 
pyrazole-NH, D2O exchangeable), 7.1-7.8 (m, 10H, Ar–H), 8.4 (s, 4H, 
2NH2, pyrazole, D2O exchangeable). 
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(Z) Ethyl-2-cyano-2-(2-(2-cyano-1-(4-methoxyphenyl)-1H-benzo 
[f] chromene-3-yl) hydrazono) acetate (17) 
Brown crystals; yield 69 %; mp 122°C; Anal Calcd (%)| for C26H20N4O4 
(452.46): C, 69; H, 4.4; N, 12.3; found (%): C, 68.1; H, 4.3; N, 12.3; IR 
(KBr, cm–1): 3357 (NH): 3008 (CH-aromatic), 2194 (CN); 1698 (C=O), 
1612 (C=N), 1573 (C=C);1H NMR (DMSO–d6, δ ppm): 1.2 (t, 3H, CH3, J = 
7.2 Hz), 4.6 (q, 2H, CH2, J = 7.2 Hz), 3.8 (s, 3H, OCH3), 6.1 (s, 1H, pyran–
H), 7.05-7.8 (m, 10H, Ar–H), 8.6 (s, H, NH, D2O exchangeable). 
3–(2,(3-Amino-5-oxo-1,5-dihydro-4H–pyrazol–4–ylidene)-
hydrazinyl)–1H-benzo[f]chromene–2–carbonitrile (18) 
Brown crystal; yield 65 %; mp 232 °C; Anal Calcd (%) for 
C24H18N6O3(438.14): C; 65.75; H, 4.14; N, 19.17; found (%): C; 65.6; 
H, 4; N, 19.2; IR (KBr, cm–1): 3325, 3209 (NH, NH2), 2197 (CN), 1680 
(C=O), 1602 (C=N), 1581 (C=C); 1H NMR (DMSO–d6, δ ppm): 3.8 (s, 
3H, OCH3), 6.01 (s, 1H, pyran–H) 7.01-7.6 (m, 10H, Ar-H), 8.1 (s, 2H, 
pyrazole–C3-NH2, D2O exchangeable); 8.2 (s, 1H, pyrazole–NH, 
D2Oexchangeable), 8.3 (s, 1H, C3–NH, D2O exchangeable). 
1-(11-Amino-12-(4-methoxyphenyl)-9-pyhenyl-12H-
benzo[5,6]chromeno[2,3-b]pyridin-10-yl)ethan-1-one (19) 
Pale bag powder; yield 45 %; mp 122 °C; Anal Calcd (%) for 
C31H24N2O3 (472.18): C, 78.78; H, 5.08; N, 5.92; found (%): C, 78.3; H, 
5.4; N, 5.8; IR (KBr, cm–1): 3325 (NH2), 3001 (CH–aromatic), 1712 
(C=O), 1666 (C=N), 1563 (C=C);1H NMR (DMSO–d6, δ ppm): 3.3 (s, 
3H, COCH3), 3.8 (s, 3H, OCH3), 6.1 (s, 1H, pyran–H), 7.1-7.8 (m, 15H, 
Ar–H), 8.6 (s, 2H, NH2, D2O exchangeable). 
2-Amino14-(4-methoxyphenyl)-4-methy-5-phenyl-14H-benzo 
[5,6]chromeno-[2,3H][1,6]naphthyridine-3-carbonitrile (20) 
Brown powder; yield 82 %; mp>300°C; Anal Calcd (%) for C34H24N4O2 
(520.19): C, 78.44; H, 4.65; N, 10.76; found (%): C, 78.3; H, 4.5; N, 10.6; IR 
(KBr, cm–1): 3320 (NH2), 3002 (CH-aromatic), 2212 (CN), 1656 (C=N), 
1560 (C=C);1H NMR(DMSO–d6, δ ppm) 3.02 (s, 3H, CH3), 3.8 (s, 3H, 
OCH3), 6.3 (s, 1H, pyran–H), 7.1-7.9 (m, 15H, Ar–H), 8.3(s, 2H, NH2);[13]C 
NMR: δ 23.1, 55.1, 63.2, 117.1, 118.1, 119.1, 123.2, 125.3, 128.1, 128.8, 
28.9, 130.1,130.2,130.6, 130.7, 130.9, 140.1, 140.2, 140.5, 140.6, 140.7, 
140.8, 140.9, 141.2, 147.1, 150.3, 151.1, 152.1, 153.1, 160.1. 
Antimicrobial activity 
The screening results are tabulated in table 1. Among all the tested 
compounds, 1-3, 5 and 8 implied their optimum antibacterial activity 
while the compounds 4, 6 and 9-13, 15 showed a moderate to weak 
antibacterial activity against B. subtilis, S. aureus, E. coli and P. 
aeruginesa. In contrast, the compounds 1, 6, 11, 15 are highly active 
against A. flavin and C. albicans while the other compounds exhibit a 
moderate to weak activity. 
 
Table 1: Antimicrobial activity of most active compounds 
Antimicrobial activity of most active compounds 





S. aureus  
(RCMB 29213) 








Test compounds 5 mg/ml 
1 19.0±0.00 20.1±0.12 23.0±0.17 18.5±0.07 13.2±0.25 15.7±1.4 
2 12.1±0.17 14.1±.05 20.1±0.04 18.1±0.25 11.0±0.77 14.7±0.25 
3 24.6±0.05 20.5±0.05 19.1±0.1 21.7±0.44 NA NA 
4 11.5±1.19 10.1±0.17 10.0±0.11 12.4±0.77 11.1±0.32 10.1±0.97 
5 18.0±0.07 19.0±0.24 12.2±0.17 12.7±0.25 13.3±0.74 11.6±0.54 
6 9.09±0.17 10.1±0.1 10.2±0.25 0.0 14.1±0.14 16.0±0.21 
7 9.9±0.11 9.1±0.51 13.4±0.14 NA 13.5±1.4 12.1±0.13 
8 16.4±0.19 14.4±0.12 17.4±0.18 20.8±0.77 NA NA 
9 9.8±0.15 10.2±0.00 11.1±0.90 9.2±0.84 10.4±1.5 NA 
10 10.0±0.05 9.7±0.10 12.7±0.25 NA 11.7±0.97 10.7±1.5 
11 8.9±0.01 NA 10.1±0.05 12.0±0.57 16.6±1.5 12.5±0.01 
12 15.0±0.06 11.1±0.11 NA 13.7±0.55 11.0±0.52 NA 
13 9.5±0.01 11.5±0.04 9.5±0.14 12.7±0.91 8.5±0.97 NA 
15 15.1±.03 12.2±0.51 11.6±0.26 13.1±0.25 11.2±0.97 13.4±1.2 
Ampicillin 26.1±0.01 21.4±0.91 25.9±0.70 26.0±0.81 NA NA 
Amphotericin 
B 
NA NA NA NA 17.4±0.58 21.7±1.2 
a: each value is the mean of three values, NA: no activity, RCMB: The Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt 
 
Structure-activity relationship (SAR) 
Based on previously obtained antimicrobial activity of chromene 
derivatives, we performed the SAR studies on their activity against 
B. subtilis, S. aureus, E. coli and P. aeruginosa, A. flavin and C. 
albicans. By inspection of the experimental results of the 
antimicrobial activity of the synthesized chromene derivatives, the 
following structural activity relationship assumptions are suggested. 
1-The pyrimidine moiety with incorporated with a sulfur atom in 
compounds 3, 5 and 8 is necessary to have higher antibacterial 
activities towards B. subtilis, S. aureus, E. coli and P. aeruginesa. 
2-It is interesting to point out that imidazole moiety in compounds 6, 
11 and 15 is necessary to have higher antifungal activity against A. 
flavin and C. albicans. The studies also emphasize the important role 
of cyano group in compound 1 in antimicrobial activity, which led to 
design new potentially active chromene, antimicrobial agents. In 
general, the above-mentioned results suggest that the new 
chromene derivatives may provide valuable leads for the synthesis 
and development of novel antifungal agents 
CONCLUSION 
In conclusion, various chromene derivatives were synthesized in 
efficient and easy process. Our study focused on the synthesis of new 
heterocyclic compounds as more powerful antimicrobial activities. In 
this research, we have shown the preparation procedure of new 
synthesized heterocyclic compounds containing a benzochromene 
moiety and evaluated the antimicrobial activities of all the innovative 
synthesized derivatives. Antimicrobial results revealed that 
compounds 4, 6 and 9-13, 15 showed a moderate to weak antibacterial 
activity against B. subtilis, S. aureus, E. coli and P. aeruginesa. In 
contrast, the compounds 1, 6, 11, 15 have higher activity towards A. 
flavin and C. albicans while the other compounds exhibit a moderate to 
weak activity. The chemical configurations of the newly synthesized 
compounds were clarified by spectroscopic techniques such as IR, 
NMR, and mass spectral data and elemental analysis. 
Zarie et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 9, 49-56 
55 
ACKNOWLEDGMENT 
Faculty of Science, Cairo University, microanalytically center for 
carrying out the biological screening. 
AUTHORS CONTRIBUTIONS 
EMAN S. ZARIE conceived the idea, supervised the experiments, 
analyzed the results and drafted the manuscript. MAHMOUD N. 
ABDELAZIZ performed the experiments. ALAADIN E. SARHAN 
contributed to the idea development. 
CONFLICTS OF INTERESTS 
Authors declare no conflicts of interest 
REFERENCES 
1. Austin DJ, Kakehashi M, Anderson RM. The transmission 
dynamics of antibiotic-resistant bacteria: the relationship 
between resistance in commensal organisms and antibiotic 
consumption. Proc R Soc London Ser B 1997;1388:1629-38.  
2. Mwambete KD, Stephen WS. Antimicrobial resistance profiles 
of bacteria isolated from chicken droppings in Dar es Salaam. 
Int J Pharm Pharm Sci 2015;7:268-71. 
3. Qingjing Y, Yanbo W, Shihui L, Jun (Joelle) W. Kinetic resolution 
and dynamic kinetic resolution of chromene by rhodium-
catalyzed asymmetric hydroarylation. Angew ChemInt Ed 
2019;58:5343-7. 
4. Hassan Y, Sarg MT, El Deeb MA, Bayoumi AH, El Rabeb SI. Facile 
synthesis and anticancer activity study of a novel series of 
substituted and fused coumarin derivatives. J Heterocycl Chem 
2018;55:1426-43. 
5. Safari J, Heydarian M, Zarnegar Z. Synthesis of 2-amino-7-
hydroxy-4H-chromene derivatives under ultrasound 
irradiation: a rapid procedure without catalyst. Arabian J Chem 
2017;10:S2994–S3000. 
6. Abd El-Wahab AHF. Synthesis, reactions and evaluation of the 
antimicrobial activity of some 4-(p-halophenyl)-4H-
naphthopyran, pyranopyrimidine and pyranotriazolopyrimidine 
derivative. Pharmaceuticals (Basel) 2012;5:745-57. 
7. Yanyang H, Rong H, Rongsheng T, Fengqiong L, Jianyou S, Mei Z. 
K2CO3 mediated synthesis of functionalized 4-substituted-2-
amino-3-cyano-4H-chromenes via michael-cyclization 
reactions. Molecules 2014;19:19253-68. 
8. Hai Feng G, Wei Wei C, Zheng F, Xin LST, Kai G. Efficient 
synthesis of chromenopyridine and chromene via MCRS. 
Chinese Chem Lett 2014;25:1357-62. 
9. Jian X, Yuye C, Shuaizhu LW, Lubin XU, Hongtao W. Diversified 
construction of chromeno[3,4-c]pyridin-5-one and 
benzo[c]chromen-6-one derivatives by domino reaction of 4-
alkynyl-2-oxo-2H-chromene-3-carbaldehyde. Adv Synth Catal 
2014; 356:1835-45. 
10. Isaac GS, Eugenia ML, Raguel PH. Enantioselective 
organocatalyzed synthesis of 2-amino-3-cyano-4H-chromene 
derivatives. Symmetry 2015;7:1519-35. 
11. Srinivas T, Athira CK, Rajeev S. Facile synthesis of 4H-chromene 
derivatives via base mediated annulation of ortho-hydroxy 
chalcones and 2-bromoallyl sulfones. Beilstein J Org Chem 
2016;12:16-21. 
12. Lamia D, Mariem K, Noureddine A, Houcine A, Souhir A. Synthesis 
and antibacterial activity of 2-aminochromenes a rising 
cyanoiminocoumarins and β-naphthol. Org Coumun 2017;10:32-9. 
13. Deepali J, Anu M, Pratbha RMS, Bhartendu PT, Senehlata Y, Jaya 
S, et al. A visible light-initiated, on pot, multi-component 
synthesis of 2-amino-4-(5-hydroxy-3-methyl-1H-pyrazol-4-yl)-
4-chromene-3-carbonitrile derivatives under solvent and 
catalyst-free conditions. Res ChemIntermed 2018;44:231-46. 
14. Hu K, Lu A, Wang Y, Zhou Z, Tang C. Chiral 
bifunctionalsquaramide catalyzed asymmetric tandem michael-
cyclization reaction; efficient synthesis of optically active 2-
amino-4H-chromen-3-carbonitrile derivatives. Tetrahedron: 
Asymmetry 2013;24:953-7. 
15. Vijay PP, Sunil UT, Balaji DR, Rajendra PP. Efficient and green 
synthesis of 2-amino-4H-chromenes. J Chem Pharm Res 
2015;7:1057-61. 
16. Kamdar NR, Haveliwala DD, Mistry PT, Patel SK. Desgin, 
synthesis and in vitro anti-mycobacterial activity of chromene 
fused cytosine and uracil analogues. Anti-infect Agents Med 
Chem 2013;1:41-7. 
17. Chetanb SN, Shah MPP, Ranjang P. Microwave assisted 
synthesis of novel 4H-chromene derivatives bearing 
phenoxypyrazole and their antimicrobial activity assessment. J 
Serb Chem Soc 2012;77:1165-74. 
18. El-Saghier AMM, Naili MB, Rammash Kh, Nabil AS, Khaled MK. 
Synthesis and antibacterial activities of some new fused 
chromenes. ARKIVOC 2007;16:83-91. 
19. Nacy T, Subin MZ. Pharmacological activities of chromene 
derivatives and overview. Asian J Pharm Clin Res 2013;6:211-5. 
20. Amol GJ, Suvidha SS, Dineshs P, Nagaiyan S. Phenylpyran-fused 
coumarin novel derivatives: a combined photophysical and 
theoretical study on the structural modification for PET-
inhibited ICT emission. Struct Chem 2018;19:217-30. 
21. Masesane IB, Desta ZY. Reaction of salicylaldehyde and 
enolates or their equivalents: versatile synthetic routes to 
chromane derivatives. Beilstein J Org Chem 2012;8:2166-75. 
22. Bogza YP, Katsiel AL, Sharpova AN, Tolstikova TG, Fisyuk AS. 
Synthesis and biological activity of 4H-thieno[3,2-c] chromene 
derivative. Chem Heter Comp 2015;50:1712-8. 
23. Okasha RM, Alblewi FF, Afifi TH, Naqvi A, Fouda AM, Al-Dies 
AM, et al. Design of new benzo[h]chromene derivatives: 
antitumor activities and structure-activity relationships of the 
2,3-positions fused rings at the 2,3-positions. Molecules 
2017;22:479-96. 
24. El Azab IH, Mohamed MY, Mahmoud AA. Microwave-assisted 
synthesis of novel 2H-chromene derivatives bearing phenyl 
thiazolidinones and their biological activities assessment. 
Molecules 2014;19:19648-64. 
25. Balalaie S, Bararjanian M, Sheikh Ahmadi M, Hekmat S, Salehi P. 
Diammonium hydrogen phosphate: an efficient and versatile 
catalyst for the one-pot synthesis of tetrahydrobenzo[b]pyran 
derivatives in aqueous media. Synth Commun 2007;37:1097–108. 
26. Abbas S, Radineh M, Omidreza F, Savis M, Ahmad R, Ramin M. 
Synthesis and cytotoxic activity of novel benzopyrano [3,2-
c]chromene-6,8-dione derivatives. Med Chem Res 
2011;20:466-74. 
27. Reddy RK, Rao SP, Dev JG, Poornachandra Y, Ganesh Kumar C, 
Rao SP, et al. Synthesis of novel 1,2,3-triazole/isoxazole 
functionalized 2H-chromene derivatives and their cytotoxic 
activity. Bioorg Med Chem Lett 2014;24:1661-3. 
28. Chen JJ, Wang TY, Hwang TL. Neolignans. acoumarinolignan, 
lignan derivatives, and a chromene: anti-inflammatory 
constituents from Zanthoxylum avicennae. J Nat Prod 
2008;71:212-7. 
29. Fang JH, Yuan QS, Jing S, Jian BC, Hai JZ, Cai XY. Colorimetric 
detection of thiols using a chromenemolecule. Org Lett 
2009;11:4918-21. 
30. Mladenovic M, Vukovic N, Sukdolak S, Solujic S. Design of novel 
4-hydroxy-chromene-2-one derivatives as antimicrobial 
agents. Molecules 2010;15:4294-308. 
31. Serbetci T, Birteksoz S, Prado S, Michel S, Tillequin F. Synthesis 
and antimicrobial activities of some sulfur-containing 
chromene derivatives. Nat Prod Commun 2012;7:891-4. 
32. Vukovic N, Sukdolak S, Solujic S, Niciforovic N. Substituted 
imino and amino derivatives of 4-hydroxycoumarins as a novel 
antioxidant, antibacterial and antifungal agents: synthesis and 
in vitro assessments. Food Chem 2010;120:1011-8. 
33. Fadda AA, Berghot MA, Amer FA, Badawy DS, Bayoumy NM. 
Synthesis and antioxidant and antitumor activity of novel 
pyridine, chromene, thiophene and thiazole derivatives. Arch 
Pharm (Weinheim) 2012;345:378-85. 
34. Mori J, Iwashima M, Takeuchi M, Saito H. A synthetic study on 
antiviral and antioxidativechromene derivative. Chem Pharm 
Bull 2006;54:391-6. 
35. Naga Sudha B, Sridhara C, Girija Sastry C, Reddy YSR, Sreevidya 
O, Lavanya S, et al. Synthesis, characterization and anthelmintic 
activity of 3-(4-acetyl-5-phenyl-4,5-dihydro-1,3,4-oxadiazol-2-
yl)-2H-chromen-2-one derivatives. Indian J Chem 
2013;52B:422-7. 
Zarie et al. 
Int J Pharm Pharm Sci, Vol 11, Issue 9, 49-56 
56 
36. Bhavsar D, Trivedi J, Parekh S, Savant M, Thakrar S, Bavishi A, 
et al. Synthesis and in vitro anti-HIV activity of N-1,3-
benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide 
derivatives using MTT method. Bioorg Med Chem Lett 
2011;21:3443-6. 
37. Cheng JF, Ishikawa A, Ono Y, Arrhenius T, Nadzan A. Novel 
chromene derivatives as TNF-alpha inhibitors. Bioorg Med 
Chem Lett 2003;3(13, Suppl 21):3647-50. 
38. Sun W, Cama LD, Birzin ET, Warrier S, Locco L, Mosley R, et al. 
6H-Benzo[c]chromen-6-one derivatives as selective ERbeta 
agonists. Bioorg Med Chem Lett 2006;16:1468-72. 
39. Hussain MK, Ansari MI, Yadav N, Gupta PK, Gupta AK, Saxena R, 
et al. Design and synthesis of ERα/ERβ selective coumarin and 
chromene derivatives as potential anti-breast cancer and anti-
osteoporotic agents. RSC Adv 2014;4:8828-45. 
40. Mungra DC, Patel MP, Rajani DP, Patel RG. Synthesis and 
identification of β-aryloxyquinolines and their pyrano[3,2-
c]chromene derivatives as a new class of antimicrobial and 
antituberculosis agents. Eur J Med Chem 2011;46:4192-200. 
41. Vijaya KP, Rajeswar RV. Synthesis and antitubercular, antiviral 
and anticancer activity of 3-(3-mercaptoalkyl-7H-[1,2,4] 
triazolo[3,4-b][1,3,4]-thiadiazin-6-yl) chromen-2-one and its 
derivatives. Indian J Chem 2008;47B:106-11. 
42. Bin L, Long Guan X, Xiao Hua X, Yong Hong L. Synthesis, crystal 
structure and herbicidal activity of 3-benzoyl-4-
hydroxycoumarin derivatives. Chin J Org Chem 2011;31:2067-73. 
43. Hegab MI, Abdulla MM. 4-Chloro-2, 2-disubstituted chromen-3-
carboxaldehyde: synthesis of some fused polycyclic 
heterocycles as an anti-inflammatory, analgesic, 
anticonvulsant, and antiparkinsonian agents. Arch Pharm 
(Weinheim) 2006;339:41-7. 
44. Ronad PM, Maddi VS, Koti BC, Kurhe YV, Swamy A, Swamy 
Ahmt, et al. Evaluation of the anticonvulsant activity of novel 
series of benzopyran-2-one derivatives by PTZ induced seizure 
model in mice. Indian J Novel Drug Delivery 2010;2:158-61. 
45. Sivakumar KK, Rajasekaran A. Synthesis, in vivo analgesic and 
in vitro anti-microbial activity of 3-amino-4-[2-(substituted 
phenyl)hydrazin-1-ylidene]-1-[(2-oxo-2h-chromen-3-
yl)carbonyl]-4, 5-dihydro-1hpyrazol-5-one and its schiff bases. 
Int J Res Pharm Chem 2014;4:517-27. 
46. Hegab MI, Abdulla MM. 4-Chloro-2,2-disubstituted chromen-3-
carboxaldehyde: synthesis of some fused polycyclic 
heterocycles as anti-inflammatory, analgesic, anticonvulsant, 
and antiparkinsonian agents. Arch Pharm (Weinheim) 
2006;339:41-7. 
47. Ronad PM, Maddi VS, Koti BC, Kurhe YV, Swamy A, Swamy 
Ahmt, et al. Evaluation of the anticonvulsant activity of novel 
series of benzopyran-2-one derivatives by PTZ induced seizure 
model in mice. Indian J Novel Drug Delivery 2010;2:158-61. 
48. Patil RB, Sawant SD. Synthesis, docking studies and evaluation 
of antimicrobial and in vitro antiproliferative activity of 5H-
chromene 4.3-d pyrimidine-2-amine derivatives. Int J Pharm 
Pharm Sci 2015;7:210-8. 
49. Sawsan AF, Sadia AH, Samir YA, Amel MF, Yousry AA. Synthesis 
of hromen-2-one, yrano[3,4-c]chromene and yridino[3,4-
c]chromeneerivatives as otentntimicrobial gents. Croat Chem 
Acta 2018;91:99-107. 
50. Al-Majedy YK, Kadhum AH, Al-Amiery AA, Mohamad A. Coumarins: 
the antimicrobial agents. Sys Rev Pharm 2017;8:62-70. 
51. Scott AC. Laboratory control of antimicrobial therapy. In: Collee 
JG. Eds. Practical Medical Microbiology. 13th edn. Edinburgh, 
Churchill Livingstone; 1989. p. 161–81. 
52. Ramadan A, Mekheimer KUS. Microwave-assisted reactions: 
three-component process for the synthesis of 2-amino-2-
chromenes under microwave heating. Chinese Chem Lett 
2009;2:271-4.
 
